If you’ve already registered, please click here to log in to the webcast.

Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking opportunities for the treatment of disease and injury. ATMPs differ from more "classic" drugs because they are not based on molecules produced by chemical synthesis but on DNA or RNA, cells and fabrics. ATMPs are an emerging sector of biomedicine, the result of the enormous progress made in the last twenty years in the field of biotechnology, and offer new opportunities for the diagnosis, prevention or treatment of serious pathologies, from genetic and chronic diseases to severe burns or injuries.

This webcast will highlight how ATMP therapies are working together with cell and gene therapies to help combat cancer, indicating that cell and gene therapies can reshape healthcare, giving hope to patients who previously had no therapeutic options. It will also demonstrate how recent solutions for GMP production in closed systems can be easily scalable, sustainable, and flexible, improving patient access while ensuring companies and hospitals maintain a competitive edge.

The webcast will show how lab productivity can be dramatically improved, enabling a complete rethink of lab facilities and showing how a well-trained workforce is crucial in driving the future of ATMPs, including compliance with regulatory authorities. BioAir (recently acquired by Tecniplast) is the leading developer of solutions for GMP production in closed systems. The presenters will propose a synergic participation model, based on co-design and engagement between healthcare, industry, and academia, to aid the identification of solutions to address a variety of health needs.

• Increase your awareness about ATMPs and their fast evolution
• Increase your knowledge about the use of closed systems for ATMP manufacturing
• Perceive how lab productivity, sustainability and flexibility can be dramatically improved through ATMP isolators